243 results about "IH Antibody" patented technology

Apparatus, methods, and computer-readable media are provided for segmentation, processing (e.g., preprocessing and / or postprocessing), and / or feature extraction from tissue images such as, for example, images of nuclei and / or cytoplasm. Tissue images processed by various embodiments described herein may be generated by Hematoxylin and Eosin (H&E) staining, immunofluorescence (IF) detection, immunohistochemistry (IHC), similar and / or related staining processes, and / or other processes. Predictive features described herein may be provided for use in, for example, one or more predictive models for treating, diagnosing, and / or predicting the occurrence (e.g., recurrence) of one or more medical conditions such as, for example, cancer or other types of disease.

Methods for identifying Quantifiable Internal Reference Standards (QIRS) for immunohistochemistry (IHC). Also disclosed are methods for using QIRS to quantify test antigens in IHC.

This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and / or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.

The invention provides an automated method of single cell image analysis which determines cell population statistic, applicable in the field of pathology, disease or cancer diagnosis, in a greatly improved manner over manual or prior art scoring techniques. By combining the scientific advantages of computerized automation and the invented method, as well as the greatly increased speed with which population can be evaluated, the invention is a major improvement over methods currently available. The single cells are identified and displayed in an easy to read format on the computer monitor, printer output or other display means, with cell parameter such as cell size and staining distribution at a glance. These output data is an objective transformation of the subjective visible image that the pathologist or scientist relies upon for diagnosis, prognosis, or monitoring therapeutic perturbations. Using our novel proposed technology, we combine the advantages provided by the clinical standard tool of flow cytometry in quantifying single cells and also retain the advantages of microscopy in retaining the capability of visualizing the immunoreactive cells. Unlike flow cytometry however, the invention uses commonly available formalin fixed immunostained tissue and not fresh viable cells. To accomplish this aim, we resort to new and improved advanced image analysis using a unique, useful, and adaptive process as described herein. The method uses multi-stage thresholding and segmentation algorithm based on multiple color channels in RGB and HS I spaces and uses auto-thresholding on red and blue channels in RGB to get the raw working image of all cells, then refines the working image with thresholding on hue and intensity channels in HS I using an adaptive parameter epsilon in entropy mode, and further separates different groups of cells within the same class, by auto-thresholding within the working image region. The Immunohistochemistry Flow cytometry (IHCFLOW) combination results in a new paradigm that is both useful, novel, and provides objective tangible result from a complex color image of tissue.

A computerized method for immunohistochemistry analysis of tissue utilizes digital images of multiple adjacent tissue sections aligned within a computerized software and processed with an algorithm to quantify a two-dimensional IHC signature score for each respective slide image. In various embodiments, the IHC score is performed over several adjacent sections and further processed to produce a three-dimensional IHC quantification referred to as an IHC signature map.

Provided is an IL-18 receptor antibody usable for immunohistochemistry, which functions as an IL-18 receptor antagonist. Also provided is a pharmaceutical composition and method for preventing and / or treating an IL-18-dependent disorder, particularly skin thickening caused by ultraviolet, using the antibody. An antibody against the IL-18 receptor α subunit, which is characterized by binding specifically to a polypeptide consisting of the amino acid sequence shown by SEQ ID NO:1, or an antibody against the IL-18 receptor β subunit, which is characterized by binding specifically to a polypeptide consisting of the amino acid sequence shown by SEQ ID NO:2, is prepared.

The present invention relates to an integrated method for enriching and detecting rare cells in biological body fluid sample. The enriching method comprises: (a) removing plasma protein by centrifugation; (b) optionally adding a red cell lysis solution to carry out red cell lysis so as to remove the red blood cells; (c) adding immunomicrospheres or immunoadsorbent to incubate; and (d) carrying out density centrifugation based on a special cell separation medium for separating the circulating rare cells, residual red blood cells after removing red blood cells and the white blood cells combined on the immunomicrospheres. The method for detecting the enriched rare cells according to the present invention comprises combining immunohistochemistry based staining with immunofluorescence, or bicolor, tricolor or multicolor staining based on immunohistochemistry, and observing and identifying by fluorescence or ordinary optical microscope or a scanner based on microscope principle. The novel and unique method for enriching and staining has been proved to have low cost and can rapidly, effectively and high specifically enrich and quantitatively detect the rare cells in blood.

Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned media of human melanoma cells that stimulates a myriad of biological activities including angiogenesis and the promotion of cell growth, survival, and differentiation through the production of lysophosphatidic acid (LPA). ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies. To study the role of ATX in the pathogenesis of malignant melanoma, we developed antibodies and small molecule inhibitors against recombinant human protein. Immunohistochemistry of paraffin embedded human tissue demonstrates that ATX levels are markedly increased in human primary and metastatic melanoma relative to benign nevi. Chemical screens identified several small molecule inhibitors with binding constants ranging from nanomolar to low micromolar. Cell migration and invasion assays with melanoma cell lines demonstrate that ATX markedly stimulates melanoma cell migration and invasion, an effect suppressed by ATX inhibitors. The migratory phenotype can be rescued by the addition of ATX's enzymatic product, LPA, confirming that the observed inhibition is linked to suppression of LPA production by ATX. Chemical analogues of the inhibitors demonstrate structure activity relationships important for ATX inhibition and indicate pathways for their optimization. These studies suggest that ATX is an approachable molecular target for the rational design of chemotherapeutic agents directed against human malignancies driven by the ATX / LPA axis, especially including malignant melanoma, among numerous others including breast and ovarian cancers.

The present invention provides a method and kit for detection of two or more target molecules in a single tissue sample, such as for gene and protein dual detection in a single tissue sample. Methods comprise treating a tissue sample with a first binding moiety that specifically binds a first target molecule. Methods further comprise treating the tissue sample with a solution containing a soluble electron-rich aromatic compound prior to or concomitantly with contacting the tissue sample with a hapten-labeled binding moiety and detecting a second target molecule. In one example, the first target molecule is a protein and the second is a nucleic acid sequence, the first target molecule being detected by immunohistochemistry and the second by in situ hybridization. The disclosed method reduces background due to non-specific binding of the hapten-labeled specific binding moiety to an insoluble electron rich compound deposited near the first target molecule.

The invention discloses a preparation method of a brain tissue rapid freezing section. According to the method, acetone is used as a freezing embedding medium and a liquid nitrogen intermediate medium, so that brain tissue can be rapidly frozen , and formation of ice crystals on the brain tissue can be effectively reduced; besides, factors affecting manufacturing quality, such as temperatures during material drawing and sectioning, fixing and soring conditions after sectioning and the like, of the freezing section are optimized, and the quality of the finally prepared section is further guaranteed. According to the brain tissue rapid freezing section obtained with the method, the freezing section which has stability and can well protect antigens and the enzyme activity is provided for further immunofluorescence, immunohistochemistry and in situ hybridization tests on the brain tissue, and a pathological section meeting requirements is provided for future clinical diagnosis related to nervous system diseases and scientific researches. Particularly, molecular and biochemical index detection can be further performed on other tissue of a mouse which is not subjected to perfusion treatment in the scientific research.

The invention relates to the technical field of biology and in particular discloses an anti-silk fibroin polyclonal antibody and a preparation method thereof. The anti-silk fibroin polyclonal antibody is produced by an animal under the condtion that polypeptide with an amino acid sequence shown in SEQ ID NO:1 is taken as an immunogen. The anti-silk fibroin polyclonal antibody has the characteristics of good specificity and high purity, can be specifically conjugated with silk fibroin and is widely applicable to immunohistochemistry, immunoblotting and in vitro immunoassay. The preparation method of the anti-silk fibroin polyclonal antibody is simple in operation and is applicable to preparation of a large quantity of anti-silk fibroin polyclonal antibodies.

A sample processing system that may be configured to achieve parallel or coincidental sample processing such as histochemical processing may involve a plurality of samples arranged for coincidental movement perhaps by use of angular microscopic slide movements to cause processing activity that may include repeated elimination and reapplication of a fluidic substance perhaps through the action of capillary motion in order to refresh a microenvironment adjacent to a sample such as a biopsy or other such sample. Snap in antibody and other substances may be included to ease operator actions and to permit location specific substance applications perhaps by including single container multiple chamber multiple fluidic substance magazines, linearly disposed multiple substance source, and primary antibody cartridges. Through refreshing of a microenvironment, depletion of the microenvironment is avoided and the time necessary for slide processing may be dramatically shortened from a more common 60 to 120 minutes to perhaps less than 15 minutes so as to permit use of such a system in an intraoperative or surgical environment such as recommended by the College of American Pathologists intraoperative guidelines or the like. Patients may thus avoid a need to be subjected to an additional surgical procedure when lab results become available to see if tumors or the like were fully removed in a prior procedure.

The invention discloses a mouse monoclonal antibody against a human Siglec-15 protein. The specificity is high, the performance is stable and the titer is high. The invention further relates to application of the monoclonal antibody to preparation of immunohistochemical detection tools for the Siglec-15 protein. According to the mouse monoclonal antibody against the human Siglec-15 protein, an immunohistochemistry method is used for detecting expression of Siglec-15 on the tumor cell surface for selection, the curative effect and the prognosis of therapeutic schedules of malignant tumors. Theinvention further relates to the application of the monoclonal antibody to preparation of antibody drugs for immunotherapy of the malignant tumors. The important application value is achieved. The adopted antibody drugs can be full-length or partial sections (Fab, F(ab)'2 or ScFv) of an Siglec-15 monoclonal antibody or combined use of the Siglec-15 monoclonal antibody and a PD-L1 monoclonal antibody. The malignant tumors mainly include colorectal cancer, endometrial cancer, thyroid cancer, bladder cancer, kidney cancer, lung cancer, liver cancer and the like.

Disclosed is a set of glass slides used for carrying out immunohistochemistry staining and storage to a tissue slice. A bearing face of an object bearing unit is provided with grooves which are different in depth and shape and are used for containing the tissue slice. The inner surfaces of the grooves are smooth. Each groove is corresponding to a mounting unit. A mounting unit sheet is matched with the shapes of the grooves. Straight lines which are vertically crossed in a vertical and horizontal mode use the centers of the mounting units as a base point and are arranged on the mounting units, each square is formed, the side length of each square is 10 micrometers, and sealing rings are arranged on the edges of the mounting units. The set of glass slides effectively avoids the problems that a tissue slice is easy to drop off, an antibody overflows, cover glass shifts, and tissue transfer is damaged in an existing immunohistochemistry detection process, is simple in structure, low in cost, and capable of well ensuring stability of the tissue slice and the cover glass and effectiveness of contact reaction of the antibody and a tissue, and can measure and calculate the size and the area of a detected tissue through scale marks on the mounting units.

A microfluidic exosome profiling platform integrating exosome isolation and targeted proteomic analysis is disclosed. This platform is capable of quantitative exosomal biomarker profiling directly from plasma samples with markedly enhanced sensitivity and specificity. Identification of distinct subpopulation of patient-derived exosomes is demonstrated by probing surface proteins and multiparameter analyses of intravesicular biomarkers in the selected subpopulation. The expression of IGF-1R and its phosphorylation level in non-small cell lung cancer (NSCLC) patient plasma is assessed as a non-invasive alternative to the conventional biopsy and immunohistochemistry. Detection of ovarian cancer also is assessed. The microfluidic chip, which may be fabricated of a glass substrate and a layer of poly(dimethylsiloxane), includes a serpentine microchannel to mix a fluid and a microchamber for the collection and detection of exosomes.

The invention provides a method for detecting endometrial receptivity through MST1 and phosphorylated MST1. The method comprises the steps that a human endometrial carcinoma cell line Ishikawa and HEK293T cells are kept and cultured in a 10% FBS and mycillin containing double-antibody DMEM / F12 culture solution; an immunoblotting experiment is carried out; co-immunoprecipitation is carried out; immunohistochemistry is carried out; adjustment of MST1 on the transcriptional activity of HOXA10 is analyzed through chromosome co-immunoprecipitation (ChIP) / PCRs; human choriocarcinoma cell (BeWo) sphere adhering experiments are carried out. According to the method, the expression level of MST1 and MST1 phosphorylation modification in endometrial tissue is detected conveniently and fast, and the receptivity state of the endometrium can be directly reflected.

The invention provides a high-specificity and high-sensitivity coordination combination anti-human TK1 antibody prepared from an antigenic determinant consisting of 23 peptide at an N end, 20 peptide at a C end and 28 peptide at the C end of human cervical cancer cells, and application thereof to tumor diagnosis. The antigenic determinant comprises the following amino acid sequences: 1) the 23 peptide (3-25) at the N end: CINLPTVLPGSPSKTRGQIQVIL: 2) the 20 peptide (206-225) at the C end: CPVPGKPGEAVAARKLFAPQ; and 3) the 28 peptide at the C end: AGPDNKENCPVPGKPGEAVAARKLFAPQ. The invention simultaneously provides a method applying the antigen for preparing the antibody. An antibody kit provided by the invention has the characteristics of high sensitivity, high specificity, low cost and the like, tumor rehabilitation populations are periodically monitored by an enhanced chemiluminescence dot blot detection method, immunohistochemistry detection and the detection kit, and the recurrence and transfer risk and the prognosis of the tumor rehabilitation people are evaluated.

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues, and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide for application, and can be used for the clinical chemotherapy of the non-small cell lung cancer.

Described herein are computer-implemented methods for analysis of a tissue sample. An example method includes: annotating the whole tumor regions or set of tumorous sub-regions either on a biomarker image or an H&E image (e.g. from an adjacent serial section of the biomarker image); registering at least a portion of the biomarker image to the H&E image; detecting different cellular and regional tissue structures within the registered H&E image; computing a probability map based on the different detected structures within the registered H&E image; deriving nuclear metrics from each of the biomarker and H&E images; deriving probability metrics from the probability map; and classifying tumor nuclei in the biomarker image based on the computed nuclear and probability metrics.

The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and immunohistochemistry. This invention is particularly advantageous because autologous muscle can be harvested from a donor site, processed and injected into target sites in the operating room. The fragmented muscle fibers can be readily integrated within the host.

The invention discloses a method for quantifying a tumor immune state based on radiomics, wherein the method comprises the following steps: S1, collecting clinical information, immunohistochemical characteristics, overall survival OS and disease-free survival DFS of tumor patients; S2, obtaining a CT image sample group of solid tumors; S3, randomly dividing the patients into a training set and a test set in proportion; S4, calculating the immunoscore by an immune marker, and dividing the patients into a set with high immune state and a set with low immune state; S5, segmenting an interest region, and extracting radiomics characteristics of the solid tumors in the interest region; S6, screening the radiomics characteristics related to the immune state from the radiomics characteristics in the training set, and training a prediction model; and S7, predicting the image immunoscore of the tumor patients, obtaining the image immune state, and then predicting the DFS and the OS in the patients. The immune state of the solid tumors such as colorectal cancer, lung cancer, gastric cancer and breast cancer is predicted by the CT image characteristics, and the analysis of pathological sections and immunohistochemistry is reduced or avoided.

The invention belongs to the biotechnology field, relates to application of PSMD4 protein, and in particular relates to application of the PSMD4 protein in preparation of a liver cancer prognostic evaluation kit. The invention adopts an immunohistochemistry technology, a microscope photograph technology and computer image processing software to test the relative transcript level of PSMD4 protein of tumor tissues relative to the tumors and determine the correlation between the relative transcript level of PSMD4 protein and the prognosis of hepatocellular carcinoma patients after operation by a manner of combining the postoperative follow-up information. The PSMD4 protein can be used for preparing a protein molecular marker for judging prognosis of the liver cancer patients, and has important instruction significance to postoperative monitor and sequential therapy of the hepatocellular carcinoma patients.

A method for detecting and quantitating multiple and unique fluorescent signals from a cell sample is provided. The method combines immunohistochemistry and a fluorescent-labeled in situ hybridization techniques. The method is useful for identifying specific subcellular components of cells such as chromosomes and proteins.

The invention provides application of METRNL protein as a protein molecule marker for detecting colon cancer and application of the METRNL protein in preparing a colon cancer diagnostic reagent or a kit. Immunohistochemistry is carried out on 30 pairs of human colon cancer tissues and para-carcinoma tissues through immunohistochemistry tests, and the result proves that the METRNL protein has differential expression in cancer tissues and para-carcinoma tissues of the human colon cancer. Therefore, whether a patient has the colon cancer can be detected according to the expression quantity of the METRNL protein in colon tissues.

The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.

The invention discloses a method for establishing a human bladder transitional cell carcinoma cell line and a mouse model of bladder carcinoma tissue recombination functional reconstruction. The method includes the primary cell culture, immortalized cell line identification, tissue reorganization and planting, HE staining, and immunohistochemistry. The invention establishes a novel stable human bladder transitional cell carcinoma cell line, and uses the cell line to construct the mouse model of bladder carcinoma tissue recombination functional reconstruction. The occurrence and development of bladder carcinoma are simulated in mice. The method researches on the biological behavior of bladder carcinoma from in vitro molecular and cell biology and in vivo animal models, and provides an effective tool for the discovery of new biomarkers and therapeutic measures.

A number of selected genes / gene products; Application of selected genes / gene products at mRNA or protein levels either singly or in combination; Application of selected genes / gene products at mRNA levels by any of the methods such as: Northern blotting, or reverse transcription and conventional PCR, or reverse transcription and quantitative real-time PCR or gene expression micro-arrays; Application of selected genes / gene products at protein levels by either Western Blotting, or immunohistochemistry, or ELISA or functional assays or gel electrophoretic separation followed by spectroscopic identification (proteamics); Application of selected genes / gene products at peptide levels derived from proteins and spectroscopic methods of identification; Detection of a hyperproliferative condition, a precancerous condition, a predisposition to develop hyperproliferative condition or cancer by applying any one of the selected genes either singly or in combination in breast tissue, breast fluid, breast cells, blood or any other tissues or cells of a mammal; Application of selected genes either singly or in combination with others for designing molecular therapeutic drugs to treat a hyperproliferative condition, a precancerous condition, or predisposition to develop hyperproliferative condition or cancer of the breast or any other tissue of a mammal; Application of selected genes either singly or in combination with others for following up of a therapeutic treatment to a hyperproliferative condition, or precancerous condition, or predisposition to a hyperproliferative condition, or cancer, of the breast or any other tissue of a mammal; Application of selected genes either singly or in combination with others for screening of therapeutic drugs to a hyperproliferative condition, or precancerous condition, or predisposition to a hyperproliferative condition, or cancer, of the breast or any other tissue of a mammal; and Application of selected genes either singly or in combination with others for designing vaccines to prevent a hyperproliferative condition, or precancerous condition, or predisposition to a hyperproliferative condition, or cancer, of the breast or any other tissue of a mammal.

The androgen receptor (AR) is the key driver of prostate differentiation and prostate cancer (PC) progression, and androgen ablation is the cornerstone of advanced PC treatment. Prostate-specific membrane antigen (PSMA) represents another target of interest in PC. Previous publications have reported inconsistent associations between androgen levels and PSMA expression. Using a panel of prototypical human PC cell lines, this relationship is clarified. PSMA is a biomarker that distinguishes AR-positive / PSMA-positive adenocarcinomas from AR-negative variants. PSMA is a cell surface barometer of androgen activity that can be readily identified by immunohistochemistry and / or in vivo imaging. Given that anti-androgen therapy is likely to remain a cornerstone of PC treatment, the associated up-regulation of PSMA, as well as its other characteristics, makes it a compelling target opportunity in PC.